These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 19479669)
21. Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer? Nabhan C J Clin Oncol; 2008 May; 26(14):2413-4; author reply 2414-5. PubMed ID: 18467737 [No Abstract] [Full Text] [Related]
22. [Adjuvant therapy of locally advanced prostate carcinoma with ibandronate]. Lindenmeir T; Ulrich M; Rau O; Reiher F; Allhoff EP Urologe A; 2007 Sep; 46(9):1287. PubMed ID: 17694295 [No Abstract] [Full Text] [Related]
23. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913 [TBL] [Abstract][Full Text] [Related]
24. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. Yuasa T Int J Urol; 2009 Sep; 16(9):731-2. PubMed ID: 19769657 [No Abstract] [Full Text] [Related]
28. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Van Poppel H Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173 [TBL] [Abstract][Full Text] [Related]
29. Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world. Thompson AL; Sarmah P; Beresford MJ; Jefferies ER BJU Int; 2017 Dec; 120(6):751-754. PubMed ID: 28834013 [No Abstract] [Full Text] [Related]
31. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013 [TBL] [Abstract][Full Text] [Related]
32. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469 [TBL] [Abstract][Full Text] [Related]
33. [Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major]. Ohlmann CH; Kohlmorgen S; Sahi D; Engelmann U; Heidenreich A Urologe A; 2007 Oct; 46(10):1425-7. PubMed ID: 17563866 [TBL] [Abstract][Full Text] [Related]
34. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473 [TBL] [Abstract][Full Text] [Related]
35. Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Di Lorenzo G Eur Urol; 2008 Feb; 53(2):332. PubMed ID: 17445974 [No Abstract] [Full Text] [Related]
36. Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Bracarda S Eur Urol; 2008 Feb; 53(2):331. PubMed ID: 17445971 [No Abstract] [Full Text] [Related]
37. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer]. Fujinami K; Miura T; Takizawa A; Osada Y Hinyokika Kiyo; 2005 Jan; 51(1):5-8. PubMed ID: 15732332 [TBL] [Abstract][Full Text] [Related]
38. Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience. Cicero G; De Luca R Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):325-31. PubMed ID: 21528780 [TBL] [Abstract][Full Text] [Related]
39. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer. Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406 [TBL] [Abstract][Full Text] [Related]
40. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]